ClinicalTrials.gg
RecruitingNCT05329792IntriNSiCUpdated Oct 6, 2023

L19IL2/L19TNF in Skin Cancer Patients

A Phase 2 interventional study of L19IL2/L19TNF in BCC - Basal Cell Carcinoma, SCC - Squamous Cell Carcinoma and Merkel Cell Carcinoma, sponsored by Philogen S.p.A.. Recruiting at 14 sites in 3 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2023-10-06.

Sponsored by Philogen S.p.A. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 5 months ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Carcinoma, Basal Cell with a site in Italy — 5 open to participants now, 6 under way, none of them phase 3. Carcinoma, Basal Cell · Italy.

Planned enrollment
11th of 15
70 · median 120
Started
2023
the only one that year
Phase 2
9 of 21
3 open now
Registered
16th of 21
by date
Lead sponsor
3 of 21
Philogen S.p.A.

Among the 21 studies in Carcinoma, Basal Cell with a site in Italy, this one is the 11th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2023, is one of 9 in phase 2, and was the 16th registered.

Carcinoma, Basal Cell

389 studies on the registry are indexed under Carcinoma, Basal Cell; 69 are open to participants now.

Browse Carcinoma, Basal Cell studies →

Open to participants now

5 of the 21 studies in Carcinoma, Basal Cell with a site in Italy are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 52 Carcinoma, Basal Cell studies recruiting now, 48 (92%) set no upper age limit and none (0%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Carcinoma, Basal Cell with a site in Italy, or all of them as a file.
02

Study summary

Phase II, open label, multicentric, proof-of-principle basket trial in patients with malignant tumors of the skin amenable to intratumoral injection, and in a curative or neoadjuvant or palliative intention.

Read the detailed description

Phase II, open label, multicentric, proof-of-principle basket trial in patients with malignant tumors of the skin amenable to intratumoral injection, and in a curative or neoadjuvant or palliative intention.

In the study, 70 patients will be enrolled and treated with a mixture of L19IL2 and L19TNF once weekly for 4 consecutive weeks. The total dose/volume will be distributed among the target lesions defined at screening via single or multiple intralesional injections, according to lesions' size and number.

Tumor assessment:

  • Tumor assessment (TA) visits will be performed at Week 12 (Day 78 from the beginning of treatment), then every 8 weeks and up to Week 52 after beginning of treatment. For confirmation of objective responses, unscheduled visits will be performed 4 weeks after the visit, which the objective response was first recorded at.
  • During each TA visit, measurement of tumor lesions and documentation (photographic documentation with use of a caliper for cutaneous lesions; ultrasound for subcutaneous lesions; imaging techniques as deemed appropriate/necessary by treating physician) will be performed. The choice of the most suitable instrumental technique to measure and document evolution of the disease will be made by the treating physician at baseline screening, the same technique will have to be used for all following tumor assessments.
  • Histological assessment of tumor tissue: estimation of percent of residual viable tumor cells and tumor infiltration with immune responsive cell. Locally performed histological specimen assessment will be centrally reviewed.

After confirmed partial responses, surgery with curative intent is allowed (if considered feasible and of potential benefit for the patients by the treating physician) and will be performed no later than 4 weeks after the TA visit at which the partial response is confirmed.

Safety assessment:

  • The safety profile of intratumoral administration of L19IL2/L19TNF will be assessed throughout the study. A complete safety assessment will be performed at the safety visit.

Human-anti-fusion protein antibodies (HAFA) assessment:

  • The possible development of antibodies against L19IL2 or L19TNF will be verified. Samples will be collected before L19IL2/L19TNF administration at Days 1, 22 and Day 78 (TA visit).

A Data and Safety Monitoring Board (DSMB), composed of expert dermato-oncologists, will evaluate safety and efficacy data after the first 20 patients and will formulate recommendations for the prosecution of the study.

03

Conditions studied

  • BCC - Basal Cell Carcinoma
  • SCC - Squamous Cell Carcinoma
  • Merkel Cell Carcinoma
  • Keratoacanthoma of Skin
  • Malignant Adnexal Tumors of the Skin (MATS)
  • Tumors From Cutaneous T-cell Lymphoma (CTCL)
  • Kaposi Sarcoma
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient participation to the present study is subjected to the positive evaluation of a local interdisciplinary tumor board, in the context of available treatment alternatives. Whatever the tumor (list of eligible tumors below) the local interdisciplinary tumor board has to consider that a local response to injection of L19IL2/L19TNF may be of benefit for the patient, in the context of this tumor and available therapeutic opportunities, benefit defined by any of the following objectives: (1) to avoid surgery considered difficult or mutilating or (2) as a treatment with the objective to permit surgery considered initially impossible, or to facilitate surgery considered difficult or mutilating, or to secure surgery considered of uncertain effect or (3) as a salvage treatment to control a tumor proved resistant to treatment alternatives or (4) as a palliative treatment improving patient comfort.
  2. Patient must have at least one skin tumor that is amenable to intratumoral injection.
  3. All tumors must be confirmed before treatment.
  4. Patients with skin tumors eligible to the present study include:

    • BCC patients with difficult-to-treat lesions: as defined by EADO operational staging system (stages IIa to IIIb) [1]. Patients must either (i) have already received, or (ii) have progressed after, or (iii) be resistant to, or (iv) not be candidate to all possible alternative treatments, including notably use or re-use of surgery, radiotherapy, hedgehog inhibitors.
    • Non- cSCC patients:

      • either advanced SCC for which a simple surgical excision is difficult or impossible, or
      • common SCC at high risk of recurrence, for which surgery alone is deemed uncertain by the tumor board, according to EADO /EORTC interdisciplinary guidelines [2]. Patients must either (i) have already received, or (ii) have progressed after, or (iii) be resistant to, or (iv) not be candidate to all possible alternative treatments, including notably use or re-use of surgery, radiotherapy, cetuximab and/or other anti-PD1 .
    • KA: particularly when surgical excision is considered as too much mutilating for this type of tumor
    • MCC: particularly when either primary tumor is considered unresectable, or skin metastases or local relapse are primarily or secondarily resistant to anti-PD1 (progress under anti-PD1). Patients must either (i) have already received, or (ii) have progressed after, or (iii) be resistant to, or (iv) not be candidate to all possible alternative treatments, including notably use or re-use of surgery, radiotherapy, and/or any anti-PD1 checkpoint inhibitors.
    • CTCL: Tumoral stage of Mycosis fungoides subtypes which are resistant to usual systemic treatments. In order to validate the first inclusion criterion of this trial, the tumor board will take into account that the treatment under investigation is intended to be only a palliative local therapy and cannot compete with a general efficacious strategy, if any.
    • KS: Classic or endemic, histologically confirmed KS, particularly when local response can be considered of either functional or cosmetic benefit. In order to validate the first inclusion criterion of this trial, the tumor board will take into account that the treatment under investigation is intended to be only a palliative local therapy and cannot compete with a general efficacious strategy, if any.
    • MATS: Advanced or MATS.
  5. Subjects must have radiographically or clinically , defined as at least one injectable lesion that is ≥ 10 mm in diameter in at least 1 dimension, or an aggregate of injectable lesions that measures ≥ 10 mm in diameter in at least 1 dimension.
  6. Subjects must be able and willing to undergo serial of injected lesion(s) and, when applicable and clinically feasible, non-injected lesions.
  7. Male or female patients from the age of 18 years.
  8. Performance Status/WHO Performance Status ≤ 1.
  9. > 10.0 g/dL.
  10. > 100 x 109/L.
  11. and AST, GGT and Lipase ≤ 1.5 x the (ULN).
  12. Serum creatinine \< 1.5 x ULN and > 60 mL/min.
  13. All acute toxic effects (excluding alopecia) of any prior therapy must have resolved to National Cancer Institute (NCI) (CTCAE v. 5.0) Grade ≤ 1 unless otherwise specified.
  14. Women of (WOCBP) must have negative pregnancy test results at screening. WOCBP must be using, from screening to three months following the last study drug administration, highly effective methods, as defined by the "Recommendations for contraception and pregnancy testing in clinical trials" issued by the Head of Medicine Agencies' Clinical Trial Facilitation Group and which include, for instance, progesterone-only or combined (estrogen- and progesterone-containing) hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone-releasing systems, bilateral tubal occlusion, vasectomised partner.
  15. Male patients with WOCBP partners must agree to use simultaneously two acceptable methods of contraception (i.e. spermicidal gel plus condom) from the screening to three months following the last study drug administration.
  16. Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Previous or concurrent cancer type that is distinct from the cancers being evaluated in this study, exception made for any other cancer curatively treated ≥ 2 years prior to study entry. Patients suffering from cSCC post-organ transplantation, or cSCC patients with concomitant chronic lymphocytic leukemia are excluded from the study.
  2. Previous topical or systemic chemotherapy, immunotherapy, or radiation therapy at the tumor sites within 4 weeks prior to study drug administration.
  3. Presence of active severe bacterial or viral infections or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or interfere with the study. In particular, a documented test for , , and Covid-19 excluding active infection is needed.
  4. Impaired cardiocirculatory functions due to any of the following conditions:

    1. History within the last year of acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris.
    2. Inadequately controlled cardiac arrhythmias including atrial fibrillation.
    3. Heart insufficiency (> Grade II, (NYHA) criteria).
    4. Any abnormalities observed during baseline and Echocardiogram investigations that are considered as by the investigator.
    5. Uncontrolled hypertension.
    6. Ischemic peripheral vascular disease (Grade IIb-IV).
  5. Known arterial aneurysms.
  6. > 3.
  7. Known uncontrolled coagulopathy or bleeding disorder.
  8. Known hepatic cirrhosis or severe pre-existing hepatic impairment.
  9. Moderate to severe respiratory failure.
  10. Active disease.
  11. Patient requires or is taking systemic or other drugs on a long-term basis. Limited use of corticosteroids to treat or prevent acute reactions and asthma/ is not considered an exclusion criterion.
  12. Known history of allergy to IL2, TNF, or other human proteins/peptides/antibodies.
  13. Pregnancy or breast-feeding.
  14. Severe diabetic retinopathy.
  15. Recovery from major trauma including surgery within 4 weeks prior to enrollment.
  16. Patient with iatrogenic or pathologic severe immune suppression.
  17. Any conditions that in the opinion of the investigator could hamper compliance with the study protocol.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Treatment arm with L19IL2 /L19TNF

    70 patients will be enrolled and treated with a mixture of L19IL2 and L19TNF once weekly for 4 consecutive weeks. The total dose/volume will be distributed among the target lesions defined at screening via single or multiple intralesional injections, according to lesions' size and number.

    Drug: L19IL2/L19TNF

Interventions

  • DrugL19IL2/L19TNF

    Drug page: Daromun

    Patients will be treated with a mixture of L19IL2 and L19TNF once weekly for 4 consecutive weeks

    Also known as: bifikafusp alfa/onfekafusp alfa

06

What researchers measure

Primary outcomes

  1. Confirmed best overall response rate (BORR)

    Efficacy of L19IL2/L19TNF measured as Confirmed best overall response rate (BORR) \[Complete Response (CR) + Partial Response (PR)\] for each tumor type measured according to RECIST v1.1 criteria. Confirmation of CR requires histopathological analysis of exeresis specimens for lesions removed by surgery or of biopsies in all other cases.

    Time frame: Visit will be performed at week 12

Secondary outcomes

  1. Disease control rate (DCR)

    Disease control rate (DCR) \[Complete Response (CR) + Partial Response (PR) + Stable Disease (SD)\] for each tumor type measured according to RECIST v1.1 criteria.

    Time frame: Visits will be performed at week 12, week 20, week 28, week 36, week 44 and week 52

  2. Local PFS (LPFS)

    Local Progression Free Survival (LPFS) on the treated tumors only

    Time frame: Visits will be performed at week 12, week 20, week 28, week 36, week 44 and week 52

  3. Progression-free survival (PFS)

    Progression-free survival (PFS), assessed separately in patients who are not resected after curative intention and in patients who undergo secondary surgery (neoadjuvant intention), whatever the RECIST response to treatment, taking into account appearance of new lesions and occurrence of metastases,

    Time frame: Visits will be performed at week 12, week 20, week 28, week 36, week 44 and week 52

  4. Adverse Events (AE)

    Percentage of Patients in Each Treatment Group with AEs, AEs with CTCAE grade ≥3

    Time frame: From the inclusion in the study (signature of the informed consent form - ICF) until the end of the trial (week 52).

  5. Serious Adverse Event (SAEs)

    Percentage of Patients in Each Treatment Group with Drug-Related Adverse Events, Serious Adverse Event (SAEs)

    Time frame: From the inclusion in the study (signature of the informed consent form - ICF) until the end of the trial (week 52).

  6. Human anti-fusion protein antibodies (HAFA)

    Assessment of the formation of human anti-fusion protein antibodies (HAFA) against L19IL2 and L19TNF

    Time frame: At week 1, at week 4 and at week 12

07

Study locations

8 of 14 sites recruiting
  • Hôpital de la Timone
    Marseille, 13 005, France
    Recruiting
    • Jean-Jacques Grob, MD · Contact
  • CHU de Nantes - Hôpital Dieu
    Nantes, 44093, France
    Recruiting
    • Gaëlle Quereux · Contact
  • Institut Gustave Roussy
    Villejuif, 94800, France
    Recruiting
    • Caroline Robert · Contact
  • IRCCS Istituto Clinico Humanitas
    Rozzano, Milano, Italy
    Not yet recruiting
    • Paolo Bossi · Contact
  • Istituto Nazionale dei Tumori Fondazione IRCCS
    Milano, 20133, Italy
    Recruiting
    • Umberto Cortinovis · Contact
  • IRCCS Istituto Nazionale Tumori "Fondazione Giovanni Pascale"
    Napoli, 80131, Italy
    Recruiting
    • Paolo Antonio Ascierto · Contact
  • Istituto Oncologico Veneto IOV
    Padova, 35128, Italy
    Not yet recruiting
    • Francesco Russano, Dr. · Contact
  • IFO- Istituto Dermatologico San Gallicano
    Roma, 00144, Italy
    Not yet recruiting
    • Pasquale Frascione, Dr. · Contact
  • Fondazione Policlinico Universitario A. Gemelli Università Cattolica del Sacro Cuore
    Roma, 00168, Italy
    Recruiting
    • Ketty Peris · Contact
  • Azienda Ospedaliero Universitaria Senese Policlinico Le Scotte
    Siena, 53100, Italy
    Not yet recruiting
    • Anna Maria Di Giacomo · Contact
  • Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI)
    Trieste, 34125, Italy
    Recruiting
    • Iris Zalaudek · Contact
  • Hospital Clinic Barcelona
    Barcelona, 08036, Spain
    Not yet recruiting
    • Agustí Toll Abelló, Dr. · Contact
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
    Not yet recruiting
    • Pablo Luis Ortiz Romero, Dr. · Contact
  • Hospital Universitario Virgen Macarena
    Sevilla, 41009, Spain
    Recruiting
    • David Moreno Ramirez, MD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Jun 2024, 15 months after the start.

Of 43 phase 2 interventional studies under Carcinoma, Basal Cell, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 67. This study's planned 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2022
First posted
Apr 15, 2022
StartActual
Mar 9, 2023
Primary completionEst.
Jun 2024
CompletionEst.
Dec 2024
Last update
Oct 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05329792
Lead sponsor
Philogen S.p.A.
Responsible party
Sponsor
First posted
Apr 15, 2022
Start date
Mar 9, 2023
Primary completion
Jun 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Oct 6, 2023

Study contacts

Lisa Nadal, PhD
Contact
regulatory@philogen.com
+39 0577 17816
Marco Taras
Contact
regulatory@philogen.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daromun

Start the discussion